title: Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine-131: a phase II study.
abstract: Eighteen consecutive patients with advanced and/or metastatic colorectal carcinoma have been treated with intraperitoneal administration of radiolabelled (iodine-131) monoclonal antibodies raised against different antigens associated to these kinds of tumours: anti-CEA FO23C5, anti-CEA BW494/32, anti-TAG B72.3, AUA1. The doses of isotope ranged between 21 and 150 mCi (777-5550 MBq) which delivered a radiation dose to the target tumour from 768 to 4628 cGy. Thirteen patients were previously treated with conventional regimens which consisted of chemotherapy (5-fluoracil with or without other anti-neoplastic drugs) both in adjuvant or palliative setting. Three patients are considered non-evaluable owing to concomitant chemotherapy in 2 and lack of objective parameters in 1. Out of 15 evaluable patients 2 achieved complete remission and 2 partial remission with a response rate of 26.6%. Three stable and 8 with progressive disease have also been registered. The toxicity was negligible consisting of hematologic WHO grade 1 in 7 patients, grade 2 in 1 patient and grade 3 in 1 patient, as well as hepatic WHO grade 1 in 8 and grade 2 in 2 patients. The authors conclude that this innovative way of treatment for advanced colorectal carcinoma seems to offer promising therapy; from these data, therefore, a new trial is justified employing radiolabelled MoAbs in well selected patients with metastatic or locally advanced colorectal carcinoma.
authors.affiliation: Nuclear Medicine Department, M. Bufalini Hospital, Cesena, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Riva
authors.forename: M
authors.initials: M
authors.lastname: Marangolo
authors.forename: V
authors.initials: V
authors.lastname: Tison
authors.forename: L
authors.initials: L
authors.lastname: Armaroli
authors.forename: G
authors.initials: G
authors.lastname: Moscatelli
authors.forename: G
authors.initials: G
authors.lastname: Franceschi
authors.forename: A
authors.initials: A
authors.lastname: Spinelli
authors.forename: G
authors.initials: G
authors.lastname: Vecchietti
authors.forename: P
authors.initials: P
authors.lastname: Morigi
authors.forename: R
authors.initials: R
authors.lastname: Tassini
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007457:Iodine Radioisotopes